EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 55c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($1.16), $0.55 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.4 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge